ReviewInternational journal of endocrinology2020

Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue.

Cristina Antinozzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.